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G12 and G13 function as molecular regulators responding to extracellular stimuli. NF-E2-related factor
2 (Nrf2) is involved in a protective adaptive response to oxidative stress. This study investigated the regulation
of Nrf2 by G12 and G13. A deficiency of G12, but not of G13, enhanced Nrf2 activity and target gene
transactivation in embryo fibroblasts. In mice, G12 knockout activated Nrf2 and thereby facilitated heme
catabolism to bilirubin and its glucuronosyl conjugations. An oligonucleotide microarray demonstrated the
transactivation of Nrf2 target genes by G12 gene knockout. G12 deficiency reduced Jun N-terminal protein
kinase (JNK)-dependent Nrf2 ubiquitination required for proteasomal degradation, and so did G13 defi-
ciency. The absence of G12, but not of G13, increased protein kinase C  (PKC ) activation and the PKC
-mediated serine phosphorylation of Nrf2. G13 gene knockout or knockdown abrogated the Nrf2 phosphor-
ylation induced by G12 deficiency, suggesting that relief from G12 repression leads to the G13-mediated
activation of Nrf2. Constitutive activation of G13 promoted Nrf2 activity and target gene induction via
Rho-mediated PKC  activation, corroborating positive regulation by G13. In summary, G12 and G13
transmit a JNK-dependent signal for Nrf2 ubiquitination, whereas G13 regulates Rho-PKC -mediated Nrf2
phosphorylation, which is negatively balanced by G12.
G-protein-coupled receptors (GPCRs) transmit signals
through conformational changes upon ligand activation and
interaction with heterotrimeric GTP-binding proteins (G pro-
teins), leading to the regulation of physiological processes. G
proteins consist of , , and  subunits and are defined by the
identity of their  subunits, which can be divided into four
families: Gs, Gi/o, Gq, and G12. Among these, the two
members of the G12 family, namely, G12 and G13, are
activated by various stimuli, including thrombin, thromboxane
A2, lysophosphatidic acid (LPA), and thyroid-stimulating hor-
mone receptors (9, 10, 31, 35, 39). G12 and G13 have been
shown to regulate a variety of cellular processes, such as actin
stress fiber formation, neurite retraction, platelet aggregation,
and apoptosis (10, 29, 35, 44).
In spite of their mostly overlapping functions, G12 and
G13 seem to differ in their abilities to couple to different
ligands and to recruit different signaling pathways for physio-
logical cellular effectors (7, 9, 12, 34, 35, 41, 42). Gene knock-
out experiments revealed that G13 deficiency resulted in
impaired angiogenesis and intrauterine death, whereas
G12
/ mice remained alive. Thus, it is most likely that G12
and G13 play a role in the cellular signaling pathways linked
to the essential biological processes of cell survival. Neverthe-
less, the regulatory factors controlled by the distinct signaling
pathway that is triggered by G12 and G13 activation have not
yet been identified. Our study has shown that oxidative stress
induces actin stress fiber formation for NF-E2-related factor-2
(Nrf2) activation (20). It is therefore possible that G12 family
members function as molecular switches responding to oxida-
tive stress.
Oxidative stress is characterized by high levels of reactive
oxygen species, which have damaging effects on cellular com-
ponents and trigger defensive responses. Nrf2 is a member of
the cap’n’collar family of bZIP transcription factors and is
expressed widely in a variety of tissues. The transcriptional
activation of antioxidant defense genes through an antioxidant
response element (ARE) depends on Nrf2 activity. Genes con-
taining a functional ARE(s) include those encoding hemeoxy-
genase 1 (HO-1), UDP-glucuronosyl transferase 1A (UGT1A),
glutathione S-transferase A1/2, NAD(P)H:quinone reductase,
and -glutamylcysteine synthetase, which play a crucial role in
defense against oxidative stress or electrophilic chemicals (30).
We previously reported that glutathione depletion or tert-
butylhydroquinone (t-BHQ) treatment enhances the nuclear
accumulation and DNA binding activity of Nrf2 (17, 18, 20).
Nrf2 activation requires phosphorylation at serine-40 by pro-
tein kinase C  (PKC ) (13, 33, 43). Despite the well-known
function of Nrf2, the upstream regulatory effectors that control
Nrf2 have not been identified. We hypothesized that G12 and
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G13 function as upstream regulators of Nrf2 activity by
responding to extracellular stimuli.
To determine whether the G12- and G13-mediated signal-
ing pathways regulate Nrf2-dependent gene transactivation, we
used mouse embryonic fibroblasts (MEFs) and animals lacking
G12 and/or G13. We investigated whether G12 and G13
transmit signals to the regulatory processes of Nrf2 and, if so,
whether they have a distinct or an overlapping role(s). Here,
we report that G12 and G13 coordinately regulate the ubiq-
uitination of Nrf2, a step required for proteasomal degrada-
tion, and that they transmit differential signals for Rho-PKC
-mediated Nrf2 phosphorylation.
MATERIALS AND METHODS
Materials. Anti-Nrf2, anti-Keap1, anti-G12, anti-G13, anti-UGT1A, anti-
hemagglutinin (anti-HA), anti-PKC , and antiactin antibodies were supplied
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-HO-1 antibody was
purchased from Stressgen (San Diego, CA). Horseradish peroxidase-conjugated
goat anti-rabbit immunoglobulin G was obtained from Zymed Laboratories (San
Francisco, CA). Constitutively activated mutants of G12 and G13 were kindly
provided by N. Dhanasekaran (Temple University, Philadelphia, PA). Small
interfering RNAs (siRNAs) for G12 and G13 and nontargeting scrambled
RNA (scRNA) were obtained from Dharmacon (Lafayette, CO). Phorbol-12-
myristate-13-acetate (PMA), GF109203X, and rottlerin were purchased from
Calbiochem (San Diego, CA). Anti-phosphorylated serine antibody, t-BHQ, and
other reagents were supplied by Sigma-Aldrich (St. Louis, MO).
Cell culture. MEFs were generated from genetically engineered mice (40) that
contained gene knockouts for rhodopsin kinase (RK) (39) and G12 and G13
(46). Cells were cultured as described previously (25).
Subcellular fractionations and immunoblot analyses. Cells were fractionated
and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
immunoblot analyses, as described previously (3, 19). Bands were developed
using the ECL chemiluminescence system (Amersham, Buckinghamshire,
United Kingdom).
siRNA knockdown. To knock down G12 or G13, cells were transfected with
siRNA directed against mouse G12 and G13, or a nontargeting scRNA (100
pmol/ml), by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. Twenty-four hours after transfection, the nu-
clear extracts prepared from the cells were used for immunoblot assays. G12 or
G13 knockdown was confirmed by immunoblot analysis.
Gel shift assay. A gel shift assay was performed as described previously (25).
A double-stranded DNA probe containing the ARE of the GSTA2 gene was used
for the gel shift analysis. The sequence of the ARE-containing oligonucleotide
was 5-GATCATGGCATTGCACTAGGTGACAAAGCA-3 (core sequences
are underlined). In some analyses, the specificity of Nrf2 binding to DNA was
determined by competition experiments. SP-1 oligonucleotide (5-ATTCGATC
GGGGCGGGGCGAGC-3) was used as a negative control.
Knockout animals. G12 homozygous knockout mice, described previously
(10), were supplied by M. Simon. Genotypes were determined by PCR assays on
tail DNA using specific primers for the respective G proteins and conditions
previously described (10).
Animal treatment and hematological analysis. Hemolysis was induced in
8-week-old mice by intraperitoneal injections of phenylhydrazine hydrochloride
(PHZ) (Sigma-Aldrich; 30 mg/kg body weight/day for 2 days) dissolved in phos-
phate-buffered saline (pH 7.4, adjusted with NaOH). Blood was collected by
retro-orbital phlebotomy using heparin-treated capillary tubes. Hematological
parameters were analyzed by using the ADVIA 1650 chemistry system (Bayer
HealthCare, Tarrytown, NY).
Transient-transfection and reporter gene assays. Transient transfection was
performed with Lipofectamine (Invitrogen, Carlsbad, CA). Briefly, cells were
incubated with the plasmid of interest and Lipofectamine reagent for 3 h. Cul-
ture medium was replaced with minimal essential medium, and cells were further
incubated for 24 h to assess gene expression. In reporter gene assays, we used the
GSTA2 promoter-luciferase construct pGL-1651 that contains the ARE (25).
Specific base substitutions were made by oligonucleotide-mediated mutagenesis
according to the manufacturer’s instructions (Stratagene). The serine-40 residue
of mouse Nrf2 was mutated to alanine using a mutagenic primer (5-GTGTTT
GACTTTGCTCAGCGACAGAAGGAC-3). The DNA sequence was verified
by using an automatic DNA sequence analyzer. Cells were transiently transfected
with pGL-1651 for 3 h in the presence of Lipofectamine reagent. The transfected
cells were incubated in Dulbecco’s modified Eagle’s medium containing 1% fetal
bovine serum for 3 h and exposed to t-BHQ (10 or 30 M) for 18 h at 37°C. The
activity of luciferase was measured by adding luciferase assay reagent (Promega,
Madison, WI).
DNA microarray. After 24 h of serum deprivation, cells were treated with
t-BHQ for 12 h and then harvested with TRIzol. Total RNAs prepared from cells
were used for microarray analyses (15). The 16,000 mouse oligonucleotide arrays
were inkjet printed by using Agilent Technologies. These arrays include 13,536
70-mers (Operon Technologies) and 2,304 65-mers (Sigma-Genosys). The ami-
noallyl method was used for the preparation of fluorescently labeled target
samples. Three independent experiments with each dye swap measurement were
conducted. Following filtering, normalization, and significance analysis of mi-
croarray, the profiles of expression changes induced by t-BHQ were calculated as
the average log2 values(treated cells divided by the control cells) that were 1,
which corresponds to twofold expression changes where P is 	0.01. The nor-
malized expression data sets were loaded into the Ingenuity software (http://www
.ingenuity.com) to identify the significantly upregulated genes with their corre-
sponding changes. In biological network analysis, the submitted genes that are
mapped to Nrf2 (the node labeled NFE2L2) in the Ingenuity Pathways Knowl-
edge Base are focused genes, which are regulated by Nrf2.
Real-time PCR analysis. Total RNA was isolated from cells using the improved
single-step method of thiocyanate-phenol-chloroform RNA extraction, and cDNA was
synthesized by reverse transcriptase using an oligo(dT) primer. Then, real-time PCR was
performed with a Light Cycler 1.5 apparatus (Roche, Mannheim, Germany) using a
Light Cycler DNA master SYBR green-I kit according to the manufacturer’s instruc-
tions. PCR was performed using the selective primers for the genes encoding UGT1A1
(sense, 5-CCAAGAGTTTGTCTTTCAAC-3; antisense, 5-AGAGGCGTTGACAT
AGGCTT-3), UGT1A6 (sense, 5-ATGCCCTGTGGTGTGATCCT-3; antisense, 5-
AGAGGCGTTGACATAGGCTT-3), GSTA4 (sense, 5-ATGTATGCAGAT GGC
ACCCAGGACCTG-3; antisense, 5-GGACAATCCTGACCACCTCAACATAG-
3), GCLM (sense, 5-CTGCCTTTGCTAAACAATTT-3; antisense, 5-TAGACTTG
ATGATTCCCCTG-3), NQO1 (sense, 5-AGGCTGGTTTGAGAGAGT-3; anti-
sense, 5-TCTGCATGCTTTCATCTG-3), HO-1 (sense, 5-GCTGTGAACTCTGTC
CAATG-3; antisense, 5-GTCAGTCAACATGGATGCTT-3) and GAPDH (glycer-
aldehyde-3-phosphate dehydrogenase) (sense, 5-TCGTGGAGTCTACTGGCGT-3;
antisense, 5-GCCTGCTTCACCACCTTCT-3). The thermal profile for SYBR green
real-time PCR was as follows: 95°C for 10 min, followed by 45 cycles at 95°C for 10 s,
54°C for 10 s, and 72°C for 15 s. A melting-curve analysis was done after amplification to
verify the accuracy of the amplicon.
Immunoprecipitation. To assess Nrf2 ubiquitination, cells were transfected
with the plasmid encoding His-tagged ubiquitin. Cell lysates were incubated with
anti-His antibody overnight at 4°C. To determine the serine phosphorylation of
Nrf2, a fraction of cell lysates was incubated with a polyclonal rabbit anti-Nrf2
antibody overnight at 4°C. The antigen-antibody complex was immunoprecipi-
tated following incubation for 2 h at 4°C with protein G-agarose. Immune
complex was solubilized in 2
 Laemmli buffer and boiled for 5 min. In another
set of assays, His-tagged ubiquitinated proteins were precipitated from cell
lysates using Ni2 affinity beads (Invitrogen). Samples were resolved and ana-
lyzed using 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
then transferred to a nitrocellulose membrane. The samples were then immu-
noblotted with the antibody directed against phosphorylated serine or Nrf2.
Statistical analysis. One-way analysis of variance procedures were used to
assess significant differences among treatment groups. For each significant effect
of treatment, the Newman-Keuls test was used for comparisons of multiple group
means. The criterion for statistical significance was set at a P of 	0.05 or 	0.01.
RESULTS
Nuclear activation of Nrf2 by G12 deficiency. To investigate
the regulatory effects of G12 and G13 on Nrf2, the nuclear
accumulation and expression of Nrf2 were monitored in
MEFs. In this study, the RK/ cells were used as a knockout
control because the physiological function of RK is restricted
to phototransduction. Preliminary experiments showed that
Nrf2 responsiveness to a prooxidant in RK/ cells was iden-
tical to that of wild-type (WT) MEFs or hepatocyte-derived
cells (HepG2 and H4IIE). We also reported that the G12-
dependent gene expression pattern in RK/ cells was identi-
cal to that in WT cells (26, 27). Nrf2 levels were minimal in the
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nuclear fraction of RK/ cells but high in that of G12
/
cells (Fig. 1A). Moreover, the level of nuclear Nrf2 seemed to
be lower in G13-deficient cells than in the control cells. The
absence of G12 and G13 did not affect the level of Keap1. To
determine whether nuclear Nrf2, increased by G12 deficiency,
is capable of binding to DNA, nuclear extracts prepared from
cells were probed with a radiolabeled ARE oligonucleotide
(Fig. 1B). An increase in the band intensity of a slowly migrat-
ing protein-DNA complex verified that nuclear Nrf2 that ac-
cumulated during the absence of G12 was active. An excess of
the ARE oligonucleotide, but not an excess of SP-1, abolished
this band retardation, supporting the specificity of Nrf2 DNA
binding. Consistent with the results of gene knockout experi-
ments, siRNA knockdown of G12 also resulted in the nuclear
accumulation of Nrf2, but knockdown of G13 failed to do so.
Except for specific knockouts, the expression levels of Nrf2 in
the lysates of the cells examined were comparable, suggesting
that G proteins might regulate the process of Nrf2 (Fig. 1C).
To confirm whether the G12 deficiency enhances Nrf2 ac-
cumulation and DNA binding activity in vivo, nuclear Nrf2
contents and band intensities of Nrf2 DNA binding complex in
the livers of mice carrying targeted mutations of the gene were
FIG. 1. Nrf2 activation by G12 deficiency. (A) Nuclear accumulation of Nrf2 by G12 deficiency. Nrf2 was immunoblotted in the nuclear or
lysate fractions prepared from knockout cells. Keap1 expression was determined in cell lysates. Graph data indicate the means  standard errors
for three separate experiments (asterisks indicate significant differences relative to RK/ MEFs [, P 	 0.05; , P 	 0.01]). (B) Increase in Nrf2
DNA binding by G12 deficiency. The arrowhead in the gel shift analysis indicates a Nrf2 DNA binding complex. Each lane contained 10 g of
nuclear extracts and 5 ng of labeled oligonucleotide. An antibody (Ab) competition experiment was carried out by incubating the samples prepared
from G12-deficient cells with specific antibodies directed against Nrf1 or Nrf2 (2 g each). (C) Nuclear accumulation of Nrf2 by G12 knockdown.
For knockdown experiments, RK/ cells were transfected with siRNAs directed against G12 or G13 or nontargeting siRNA. RK
/ cells were
used as a knockout control, which is irrelevant to the function of endogenous G protein in MEFs.
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determined. In G12 gene knockout mice, the nuclear local-
ization of hepatic Nrf2 was greatly increased and was accom-
panied by increased Nrf2 activity compared to that in WT
control mice (Fig. 2A). In this series of experiments, we used
G12 knockout animals because the G13 knockout mutation
resulted in intrauterine death (40). To assess changes in the
representative Nrf2 target genes, we next examined the levels
of HO-1 and UGT1A in the livers of the mice. G12 gene
knockout induced HO-1 and UGT1A in the livers of mice (Fig.
2B), which further supported an in vivo function of G12 in
Nrf2 regulation. In an effort to assess functional changes for
the activation of Nrf2 and its target gene induction, we next
FIG. 2. Nrf2 activation by targeted disruption of the G12 gene in mice. (A) Gel shift assay. Nrf2 activation was measured in the livers of G12
knockout mice. The specificity of Nrf2 DNA binding was determined by a competition experiment using the unlabeled ARE or SP-1 binding
oligonucleotide. An antibody competition experiment was carried out by incubating the samples prepared from G12 knockout mice with specific
antibodies (2 g each). Data indicate the means  standard deviations (three animals) (, significant compared to WT at a P of 	0.01).
(B) Induction of HO-1 and UGT1A by targeted disruption of the G12 gene in mice. HO-1 and UGT1A were immunoblotted with antibodies in
the liver homogenates of the WT or homozygous G12 knockout mice (three animals each). Representative blots are shown. (C) Plasma bilirubin
levels. Total, direct, and indirect bilirubin contents in the blood of WT or G12 knockout mice were determined before and 24 h after PHZ
injections (30 mg/kg body weight/day intraperitoneally for 2 days) (seven animals; , significant compared to the respective parameters of
vehicle-treated WT animals at a P of 	0.01; †, significant compared to the respective parameters in vehicle- or PHZ-treated WT animals at a P
of 	0.05).
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determined whether G12 deficiency accelerates the metabo-
lism of heme into bilirubin and its glucuronosyl conjugations,
which are catalyzed by a series of Nrf2 target genes, including
HO-1 and UGT1A (22, 23). As expected, the catabolism of
heme into bilirubin and bilirubin glucuronide conjugations
were both significantly enhanced by the absence of G12 (Fig.
2C). Furthermore, we comparatively evaluated the effects of
PHZ on bilirubin production and glucuronosyl conjugations in
WT and G12 knockout animals because PHZ induces hyper-
bilirubinemia via chemical hemolysis (Table 1) (36, 38). An
intraperitoneal injection of C57BL6 mice with PHZ resulted in
marked increases in total and conjugated bilirubin contents in
blood (Fig. 2C). As expected, the injection of PHZ into G12
knockout mice caused significantly greater increases in total
and glucuronidated bilirubin concentrations, indicating that
the induction of HO-1 and UGT1A by G12 deficiency con-
tributed to the metabolism of a larger amount of heme into
bilirubin and the subsequent glucuronosyl conjugations.
To determine the effects of G12 or G13 deficiencies on the
activation of Nrf2 by a prooxidant, we next examined the ef-
fects of t-BHQ on Nrf2 in MEFs. t-BHQ treatment for 6 or
12 h increased nuclear Nrf2 content in WT and RK/ MEFs
(Fig. 3A), which returned to basal levels at 24 h. In G12
/
cells, t-BHQ treatment began to enhance nuclear Nrf2 content
at 3 h, and this was increased at 6 h to maximum levels, which
were maintained for at least 24 h. t-BHQ treatment only
weakly increased nuclear Nrf2 levels in G13-deficient cells. A
greater increase in Nrf2 activation by t-BHQ, under conditions
of G12 deficiency, was also observed in the gel shift assays
(Fig. 3B). Competition experiments using specific antibodies
and excessive amounts of unlabeled oligonucleotides con-
firmed the specificity of the band of the slowly migrating com-
plex.
As part of our functional studies on the regulation of Nrf2 by
G12 and G13, we examined the transactivation of the pGL-
1651 GSTA2 luciferase gene, which contains the ARE. In
RK/ cells, t-BHQ treatment increased luciferase expression
by pGL-1651 (Fig. 3C). Luciferase expression was promoted by
t-BHQ to a greater extent in G12
/ cells than in control or
G13
/ cells. Our data indicate that G12 deficiency enhances
the nuclear accumulation of Nrf2 that is active for target gene
transactivation. In addition, treatment of the RK/ cells with
LPA (5 M for 12 h), a representative ligand that activates
GPCRs coupled to G12 and G13, led to nuclear accumula-
tion of Nrf2 (Fig. 3D, gels). This is in line with prooxidant
production caused by LPA treatment (6). As expected, LPA
treatment induced luciferase expression from pGL-1651 in
RK/ cells (Fig. 3D, graph). G12 deficiency further pro-
moted the gene induction by LPA, whereas G13 deficiency
prevented the gene expression.
Microarray profiles. To determine changes in Nrf2-medi-
ated target gene induction, we carried out profiling of t-
BHQ-responsive gene expression (12 h) in cells by using
oligonucleotide microarrays. The expression of antioxidant
and phase II enzymes was enhanced after treating RK/
cells with t-BHQ. The absence of G12 significantly en-
hanced the ability of t-BHQ to stimulate a battery of Nrf2
target genes compared with that of the control; these genes
included Txnrd1, Gsr, Gclm, Gclc, Gsta4, and Gsta2 (Table
2). The smaller changes observed in the relative increases of
Gstm1 and UGT1A6 mRNAs by t-BHQ in G12
/ cells
compared to those in the control may have been due to their
higher basal expression (Table 2). Ingenuity pathway anal-
ysis in the network validated glutathione and cysteine me-
tabolism as significant pathways potentiated by G12 defi-
ciency. Genes not differentially expressed by the absence of
G12 were omitted from the Ingenuity pathway analysis. All
the enhanced genes, including Gsta1, Gsta3, Gsta4, Gstp1,
Gclc, Gclm, G6pd, and Gsr, appeared to be regulated by
Nrf2 in the map (Fig. 4A).
We verified these results by real-time PCR analyses. Rela-
tive increases in UGT1A1, UGT1A6, GSTA4, GCLM, NQO1,
and HO-1 mRNA levels by t-BHQ were all greater in G12
/
cells than in control or G13
/ cells (Fig. 4B). Diethylmaleate
(1 mM, 6 h) or sulforaphane (10 M, 6 h) treatment caused
similar changes in the genes’ expression (data not shown).
These data were consistent with the results of the microarrays,
confirming that Nrf2 activated by the absence of G12 was
functionally active in increasing its target gene mRNAs. Im-
munoblot assays confirmed the greater induction of HO-1 and
UGT1A proteins by t-BHQ in G12
/ cells (see Fig. S1 in the
supplemental material).
G12- and G13-dependent ubiquitination of Nrf2. Nrf2 is
degraded by the 26S proteasome system after multiple ubiq-
uitinations (37). To understand in more depth the molecular
mechanism underlying Nrf2 activation by G12 deficiency, we
tested the possibility that G12 mediates a signal for Nrf2
ubiquitination that would lead to proteasomal degradation.
Immunoprecipitation and the immunoblot detection system
indicated that the absence of G12 basically eliminated Nrf2
TABLE 1. Hemolytic parameters in WT and G12 knockout mice
a
Mouse genotype and
treatment No. of RBC
b (109/ml) Iron concn (g/dl) Body wt (g) Liver wt/100 gbody wt
Spleen wt/100 g
body wt
Wild type
Vehicle 10.67  0.39 108  23 23.9  2.0 3.75  0.42 0.23  0.04
PHZ 6.94  0.73** 158  52* 25.9  3.0 4.07  0.33 0.64  0.23**
G12
/
Vehicle 10.11  0.15 119  28 25.1  1.8 3.60  0.29 0.26  0.03
PHZ 6.49  0.88** 160  27* 24.0  2.0 3.89  0.46 0.50  0.11**
a Mice were treated intraperitoneally with PHZ (30 mg/kg body weight/day for 2 days) and subjected to analyses 24 h after treatment. Values are means  standard
deviations. Asterisks represent significant difference from values for vehicle treatment of the same genotype (seven animals; *, P 	 0.05; **, P 	 0.01).
b RBC, red blood cells.
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ubiquitination compared to that of the control (Fig. 5A, upper
left panel). As reported, t-BHQ treatment inhibited Nrf2 ubiq-
uitination in the control cells. Thus, our data suggest that G12
contributes to the Nrf2 ubiquitination step. An in vivo ubiq-
uitination assay using a His-tagged ubiquitin construct and
Ni2 affinity beads verified polyubiquitination of Nrf2 in the
RK/ cells (Fig. 5A, upper right panel). G12 and G13
deficiencies also decreased polyubiquitination of Nrf2. Studies
have shown that JNK is involved in the proteasomal degrada-
tion of certain transcription factors (1, 11). Previously, we
proposed a possible role for G12 and G13 in the JNK-de-
pendent degradation of phosphorylated IB (19). Therefore,
we assessed the role of JNK in Nrf2 ubiquitination. The en-
dogenous JNK expression levels were not changed by a defi-
ciency of G12 or G13 (see Fig. S2A in the supplemental
material). In RK/ cells, the inhibition of JNK using
SP600125 reduced the accumulation of ubiquitinated Nrf2 and
reciprocally increased nuclear Nrf2 content (Fig. 5A, lower left
FIG. 3. Nrf2 activation and target gene promotion by t-BHQ. (A) Effects of t-BHQ treatment on nuclear accumulation of Nrf2. Nrf2 contents
were measured in the nuclear fractions of cells treated with vehicle or t-BHQ (30 M). A positive control (PC) represents t-BHQ-treated RK/
cells (12 h). (B) Nrf2 DNA binding activities. Gel shift assays were performed using the nuclear extracts of t-BHQ-treated cells. An antibody
competition experiment was carried out by incubating the samples prepared from untreated or t-BHQ-treated cells with specific antibodies directed
against Nrf1 or Nrf2 (2 g each). (C) pGL-1651 reporter assays. Luciferase activity was measured in the lysates of pGL-1651-transfected cells
treated with t-BHQ (10 or 30 M, 18 h). Data indicate the means  standard errors for four separate experiments (asterisks indicate significant
differences relative to the respective control [, P 	 0.05; , P 	 0.01]). (D) Effects of LPA treatment on nuclear Nrf2 levels and pGL-1651
reporter activities. Nrf2 contents and pGL-1651 activities were measured in cells treated with vehicle or 5 M LPA for 12 h and 24 h, respectively.
Data indicate the means  standard errors for three separate experiments (asterisks indicate significant differences relative to the control [, P 	
0.05; , P 	 0.01]).
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panel). We then monitored the effect of the ectopic expression
of JNK on Nrf2 ubiquitination. When G12
/ cells were
transfected with a plasmid encoding HA-JNK, the ubiquitina-
tion of Nrf2 was substantially increased with a decrease in
nuclear Nrf2 levels (Fig. 5A, lower right panel).
We performed similar experiments using G13
/ cells and
unexpectedly found that G13 deficiency also inhibited Nrf2
ubiquitination (Fig. 5B). Transfection of G13
/ cells with
HA-JNK allowed Nrf2 ubiquitination, which was less pro-
nounced than that seen in transfected G12
/ cells (Fig. 5B).
Also, we found that constitutive activation of G12 (G12Q229L
or G12QL) and G13 (G13Q226L or G13QL) notably en-
hanced Nrf2 ubiquitination in RK/ cells, which was pre-
vented by either transfection with a dominant negative mutant
of JNK (DN-JNK) or chemical inhibition of JNK (Fig. 5C). In
this experiment, the cells were simultaneously transfected with
G12QL and G13QL because both are involved in the ubiq-
uitination step. Collectively, these findings indicate that the
signaling pathways transmitted by both G12 and G13 regu-
late Nrf2 ubiquitination in conjunction with JNK, thereby pre-
sumably controlling Nrf2 degradation. Keap1 is required for
the formation of the proteasomal complex that degrades Nrf2.
Next, we determined the interaction between Keap1 and Nrf2.
Keap1 binding to Nrf2 was decreased notably by G12 defi-
ciency and moderately by G13 deficiency (Fig. 5D), supporting
the concept that the G proteins regulate the ubiquitination and
degradation of Nrf2. Given the reciprocity of the changes in the
levels of ubiquitinated and activated Nrf2, we sought to investi-
gate the activating process of Nrf2 that is possibly linked to ubiq-
uitin-mediated proteasomal degradation.
Differential activation of Nrf2 by G12 and G13. Our
finding of Nrf2 activation by G12 deficiency suggested that G12
represses Nrf2 activation such that a lack of G12 facilitates an
activating signal. Hence, we reasoned that G12 negatively regu-
lates the Nrf2-activating signal transmitted from G13. Accord-
ingly, we examined the effect of the transfection of an activated
mutant form of G12 on Nrf2 activation in cells lacking G protein.
The transfection of G12QL into G12
/ cells decreased nuclear
Nrf2 content and DNA binding activity (Fig. 6A), whereas the
transfection of G13QL into G13
/ cells notably increased
both. In the rescue experiments using RK/ cells, G13QL in-
creased the basal nuclear Nrf2 content, whereas G12QL trans-
fection decreased t-BHQ-inducible nuclear accumulation of Nrf2
(Fig. 6A). G13WT transfection in combination with LPA en-
hanced nuclear Nrf2 accumulation.
PKC  is responsible for Nrf2 phosphorylation at a serine
TABLE 2. Effects of t-BHQ on the representative antioxidant enzyme gene expression
Gene Gene product nameb
Relative change in gene expression in cells with
indicated genotypea
RK/ G12/ G13/
Antioxidant enzyme genes
Hmox1 Heme oxygenase (decycling) 1 9.90 13.11 11.59*
Txnrd1 Thioredoxin reductase 1 1.50** 5.97*† 2.19*
Gsr Glutathione reductase 1 1.16 2.85*† 2.13*
Cat Catalase 1.18 2.20* 1.38**
Prdx1 Peroxiredoxin 1 1.27 NA 1.56
Xenobiotic metabolism genes
Nqo1 NAD(P)H dehydrogenase quinone 1 4.32 16.01** 3.13**
Gclm Glutamate-cysteine ligase modifier subunit 2.30* 10.39**‡ 2.22**
Gclc Glutamate-cysteine ligase catalytic subunit 2.16* 9.72**‡ 3.27**†
Gsta4 Glutathione S-transferase alpha 4 3.64* 7.27**† 3.69**
Gsta3 Glutathione S-transferase alpha 3 NA 5.51 1.13
Gsta2 Glutathione S-transferase alpha 2 (Yc2) 1.10 3.43*† 2.71*‡
Gstp1 Glutathione S-transferase pi 1 1.37* 2.40 1.43*
Gss Glutathione synthetase 1.39 2.31 1.37*
Gsto1 Glutathione S-transferase omega 1 1.87** 1.84 1.66*
Gstm3 Glutathione S-transferase mu 3 1.51 1.82* 1.88**
Gstm1 Glutathione S-transferase mu 1c 2.60** 1.54† 3.00**
UGT1A6 UDP glycosyltransferase 1 family A6d 2.98** 1.40† 2.55**†
Nqo2 NAD(P)H dehydrogenase quinone 2 1.62* 1.19 1.21
Mgst1 Microsomal glutathione S-transferase 1 2.07* 1.15 1.84*
Gstm4 Glutathione S-transferase mu 4 1.09 1.14 0.94†
Gstk1 Glutathione S-transferase kappa 1 0.91 1.09 0.86
Gstm5 Glutathione S-transferase mu 5 1.03 0.93 1.03
Mgst3 Microsomal glutathione S-transferase 3 1.03 0.92 1.21
Gstm6 Glutathione S-transferase mu 6 1.43 0.84 1.29*
Gstz1 Glutathione S-transferase zeta 1 0.95 0.82 0.87
Gstm2 Glutathione S-transferase mu 2 1.52 0.66 1.25*
Gstt3 Glutathione S-transferase theta 3 1.33 0.65 NA
Gstt1 Glutathione S-transferase theta 1 0.78** 0.50 0.81
a Each value indicates the relative change after t-BHQ treatment (30 M, 12 h). Asterisks indicate significant difference from value for vehicle treatment (*, P 	
0.05; **, P 	 0.01). Daggers indicate significant difference from RK/ values (†, P 	 0.05; ‡, P 	 0.01). NA, data not available.
b Genes for products in bold are Nrf2 dependent.
c Basal mRNA content was 2.4-fold greater in G12/ cells than in control cells.
d Basal mRNA content was 42-fold greater in G12/ cells than in control cells.
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residue (serine-40), which is required for Nrf2 activation (11).
In G12
/ cells, Nrf2 transfection greatly enhanced luciferase
expression from pGL-1651. In contrast, transfection with mu-
tant Nrf2 (where serine-40 is replaced with alanine) failed to
induce the gene (Fig. 6B). These data support the association
of G12 and G13 with Nrf2 phosphorylation. In an attempt to
identify the downstream effector required for Nrf2 phos-
phorylation, we investigated whether cell signals from G12
and G13 regulate PKC  activation. A deficiency of G12, but
not of G13, caused PKC  activation, as evidenced by its
translocation from the cytoplasm to the plasma membrane
(Fig. 6C). However, the expression of PKC  was unchanged in
cell lysates. To examine whether G13 positively regulates the
signal for Nrf2 activation, the effect of G13QL transfection on
PKC  activation in G13
/ cells was examined/. It was
observed that G13QL transfection increased PKC  content in
the membrane fraction and that this occurred with a commen-
surate decrease of PKC  content in the cytoplasm. Our data
indicate that either a G12 deficiency or G13 activation pro-
motes PKC  activation.
FIG. 4. Microarray profiles and validation. (A) Biological network analysis of Nrf2 (NFE2L2). This network map depicts the relationship
between Nrf2 and Nrf2-regulated genes. Bold characters are focused genes whose t-BHQ-inducible expression (30 M, 12 h) is potentiated by
G12 deficiency. A greater intensity of red indicates a higher degree of upregulation. The distance and label between nodes indicate the extent and
type of relationship of the interactions involved with Nrf2, respectively. The score of each node is displayed as normalized log2 (treated/control)
value. (B) Real-time PCR analyses. The expression of representative Nrf2 target genes was analyzed by real-time PCR assays, in which the mRNA
level of GAPDH was used as a reference for data normalization. Cells treated with vehicle or t-BHQ (30 M, 12 h) were subjected to the
preparation of mRNA, from which cDNA was synthesized by reverse transcriptase. Changes (n-fold) were calculated by correlation coefficients
of crossing point for triplicate PCR results.
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To determine whether PKC  activates Nrf2 in these cells,
we examined the serine phosphorylation of Nrf2. The absence
of G12 distinctly increased Nrf2 phosphorylation at the serine
residue, whereas the absence of G13 failed to do so (Fig. 6D,
upper panel). Glycogen synthase kinase 3, another substrate
of PKC , was also phosphorylated by G12 deficiency but not
by G13 deficiency (Fig. 6D, lower panel).
Consistent with PKC  activation, G13QL transfection in-
creased Nrf2 phosphorylation. To link PKC  activation and
Nrf2 phosphorylation, we investigated Nrf2 phosphorylation
after PKC inhibition using PMA and GF109203X (a selective
PKC inhibitor), both of which abolished Nrf2 phosphorylation
enhanced by G12 deficiency (Fig. 6E). Moreover, rottlerin (a
specific PKC  inhibitor) had the same effect. G13QL-induced
Nrf2 phosphorylation was also blocked by the chemical inhi-
bition of PKC activity.
We wondered whether Nrf2 activation by G12 deficiency re-
sulted from an activating signal transmitted from G13 due to
relief from G12-mediated inhibition. To determine whether Nrf2
activation that is increased by G12 deficiency is mediated by
G13, we examined the effects of G13 knockout or knockdown
on PKC-dependent Nrf2 phosphorylation. Serine phosphoryla-
tion of Nrf2 in G12
/ cells was substantially reduced by siRNA
knockdown of G13 (Fig. 6F). Consistently, the level of Nrf2
phosphorylation was much lower in G12 and G13 (G12/13)
double-knockout cells than in G12 knockout cells. Our data
FIG. 5. Effects of G12 and G13 deficiencies or JNK transfection on Nrf2 ubiquitination. (A) Role of G12 on Nrf2 ubiquitination. Cells
transfected with the plasmid encoding His-tagged ubiquitin (His-Ubi) were incubated with 10 M MG132 (a proteasomal inhibitor) for 6 h. When
cells were treated with t-BHQ (30 M, 12 h) or SP600125 (10 M, 6 h), MG132 was added 1 h earlier. Ubiquitinated proteins were immuno-
precipitated (IP) with anti-His antibody in lysates and subjected to immunoblottings (IB) for Nrf2. The nuclear Nrf2 levels were comparatively
assessed. The effects of HA-JNK were similarly measured. In addition, whole-cell extracts were incubated overnight with Ni2 affinity beads. After
being washed with lysis buffer, the beads were boiled in the sample buffer and the eluate was immunoblotted for Nrf2 (upper right panel). (B) Role
of G13 in Nrf2 ubiquitination. Assays were performed as described for panel A. (C) JNK-dependent ubiquitination of Nrf2 increased by activated
mutants of G12 and G13. (D) Interaction of Keap1 and Nrf2. Immunoprecipitated Keap1 was subjected to immunoblotting for Nrf2.
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support the conclusion that a signal transmitted from G13 reg-
ulates PKC -dependent Nrf2 phosphorylation and that this is
counter balanced by G12.
Rho-mediated Nrf2 activation by G13QL during G12 de-
ficiency. The finding that G13 transmits a regulatory signal for
Nrf2 activity prompted us to confirm whether G13 activation
could further increase ARE-mediated gene transactivation
during G12 deficiency. G13QL transfection into G12 knock-
out or G12/13 double-knockout cells strongly enhanced
luciferase expression from pGL-1651 (Fig. 7A, left). In the
G12/13
/ cells, G13 activation further increased t-BHQ-
inducible expression of the Nrf2 target gene. Deletion of the
ARE site in pGL-1651 completely abolished reporter gene
activity, verifying the essential role of the ARE for Nrf2-me-
FIG. 6. Regulation of Nrf2 by G12QL or G13QL. (A) Nuclear contents and DNA binding activities of Nrf2. Immunoblot and gel shift assays
were performed with the nuclear extracts prepared from cells transfected with empty vector, G12QL, or G13QL. Cells were treated with 30 M
t-BHQ or 5 M LPA for 12 h. (B) pGL-1651 reporter assays. Luciferase activity was measured in the lysates of G12-deficient cells transfected
with pGL-1651 with or without the plasmid encoding Nrf2 or mutant Nrf2 (serine-40 replaced with alanine). Data indicate the means  standard
errors for four separate experiments (asterisks indicate significant differences relative to the respective control [, P	 0.05; , P	 0.01]). (C) PKC
 activation. PKC  was immunoblotted (Western blotted [WB]) in subcellular fractions. (D) Nrf2 phosphorylation. Serine-phosphorylated Nrf2
was immunoblotted with antiserine antibody in Nrf2 immunoprecipitates. Phosphorylation of glycogen synthase kinase 3 was assessed as a positive
control for PKC  activity. IP, immunoprecipitation; PS, phosphoserine. (E) Effects of PKC inhibition on Nrf2 phosphorylation. Serine phospho-
rylation of Nrf2 was assessed in cells treated with vehicle, PMA (10 M, 18 h), GF109203X (5 M, 6 h), or rottlerin (5 M, 6 h). (F) Role of G13
in Nrf2 phosphorylation by G12 deficiency. Serine phosphorylation of Nrf2 was determined in the knockdown or knockout cells indicated.
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diated gene activation (Fig. 7A, middle panel). In RK/ cells,
G13QL also induced pGL-1651 transactivation, whereas
G12QL prevented the ability of t-BHQ to induce pGL-1651
transactivation (Fig. 7A, right panel). Immunoblot analysis
confirmed that G13QL transfection into the G12/13
/ cells
further promoted both PKC  activation (data not shown) and
PKC-mediated Nrf2 phosphorylation, compared with empty-
vector transfection (Fig. 7B). Moreover, the strong promotion
of Nrf2 target genes by G13QL in the double-knockout cells
supports the conclusion that G13 indeed mediates a positive
signal for Nrf2 activation.
Rho is a central molecular effector which is involved in a
variety of cellular functions and can be regulated by many
receptors. Since G13 activates Rho (4, 9), we studied the role
of Rho in Nrf2 activation by G13QL. Transfection with DN-
Rho inhibited the ability of G13QL to activate Nrf2 or to
induce luciferase from pGL-1651 in G12/13
/ cells (Fig. 7C).
Consistent with this, DN-Rho reversed the serine phosphory-
lation of Nrf2 by G13QL (Fig. 7D). The basal Rho expression
levels were very weak but comparable among the MEFs (data
not shown). Our data indicate that the G13 pathway to Nrf2
activation involves Rho. Taken together, these observations
indicate that PKC -mediated Nrf2 phosphorylation and its
target gene transcription require Rho activity downstream
of G13.
DISCUSSION
Increases in sensitivity to carcinogen and tumorigenesis in
Nrf2-deficient mice support the concept that Nrf2-mediated
gene transcription is essential for the prevention of chemical
carcinogenesis by cytoprotective agents. Nrf1 and Nrf2 also
play critical roles in fetal development and antioxidant defense
(32). The main function of Nrf2 is to protect cells from oxida-
tive stress (47). Here, we report the differential role of G12
and G13 in terms of the regulation of Nrf2. Our knockout and
FIG. 7. Rho-mediated Nrf2 activation by G13QL during G12 deficiency. (A) pGL-1651 reporter activities. Luciferase assays were performed
with the lysates of cells transfected with G13QL or G12QL (0.3 g plasmid each). To assess the combined effect of G13QL and t-BHQ,
G12/13
/ cells transfected with 0.1 g G13QL were treated with 10 M t-BHQ. Data represent the means  standard errors for four separate
experiments (, significant compared to control at a P of 	0.01). (B) PKC  activation by G13QL in G12/13
/ cells. (C) Effects of DN-Rho
on Nrf2 activation and luciferase induction by G13QL. (D) Effect of DN-Rho on serine phosphorylation of Nrf2 by G13QL. IP, immunopre-
cipitation; WB, Western blotting.
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knockdown results revealed the inhibitory role of G12 in Nrf2
activity, which was further supported by the finding that
G12QL reversed Nrf2 activation and target gene induction
due to G12 deficiency. The observation that HO-1 protein,
whose expression depends on Nrf2, was markedly induced in
G12
/ cells verifies the functional activation of Nrf2 by G12
deficiency. Furthermore, hepatic induction of HO-1 and
UGT1A in G12 knockout mice provided compelling evidence
that G12 regulates Nrf2 in vivo, demonstrating the physiolog-
ical importance of G12 in Nrf2 activity. Moreover, the finding
that the basal and hemolysis-inducible bilirubin production
and glucuronosyl conjugations were both elevated during G12
deficiency implies that the specific G proteins physiologically
contribute to heme catabolism and metabolic excretion of
bilirubin via Nrf2 regulation.
Microarray and real-time PCR results demonstrate that
G12 deficiency markedly enhanced the ability of t-BHQ, an
Nrf2 activator, to transactivate Nrf2 target genes. Quantitative
real-time PCR assays validated the microarray results that
provide only predictive values. In the PCR assays, UGT1A1,
1A6, GCLM, and NQO1 gene transcripts were included be-
cause the genes comprised the functional AREs (our cus-
tomer-made microarrays did not cover all of the genes con-
taining functional AREs). The observation showing strong
induction in the genes participating in glutathione metabolism
(i.e., Gsta1, Gsta3, Gsta4, Gstp1, Gclc, Gclm, G6pd, and Gsr)
(14) supports the significant role of G12 in Nrf2 activity.
Canonical pathway analysis successfully confirmed glutathione
and cysteine metabolism as the major pathways influenced by
G12 deficiency in combination with t-BHQ treatment.
Changes in the levels of UGT1A1, 1A6, and GCLM transcripts
correlate well with those in pGL-1651 expression. In this work,
t-BHQ was used to promote the expression of target genes
because G12 deficiency alone affected only a few. Weak acti-
vation of Nrf2 by t-BHQ in G13
/ cells suggested that G13
positively regulates a cell signal for Nrf2 activation. Neverthe-
less, t-BHQ slightly enhanced Nrf2 activity in G13
/ cells,
suggesting the role of another minor pathway(s) that might
stimulate Nrf2 during the absence of G13. The lack of a
repressing effect on certain genes (i.e., the GSTA4 and HO-1
genes) by G13 deficiency might be due to possible changes in
other transcription factors.
Nrf2 and Keap1 are sulfhydryl-containing sensor molecules
that respond to oxidative stress (47). Moreover, the Kelch
repeat of Keap1 interacts with Neh2 of Nrf2 (13, 37). Initially,
it was believed that Keap1 binds with and sequesters Nrf2 in
the cytoplasm for repression (16). However, it is now accepted
that Keap1 degrades Nrf2 in the resting state and that a de-
crease in Keap1 activity by prooxidant leads to Nrf2 activation.
In the present study, Keap1 expression was unchanged by G12
and G13 deficiencies, suggesting that the nuclear accumula-
tion of Nrf2 during the absence of G12 is not due to changes
in Keap1 expression. The actin architecture provides scaffold-
ing for Keap1 and thus controls Nrf2 function (21). Lysine
residues within Nrf2 constitute the acceptor sites for Keap1-
targeted Nrf2 ubiquitination or stabilization (28). According to
our additional studies, nuclear Keap1 content is slightly re-
duced in the absence of G12. Moreover, Keap1 binding to
Nrf2 was decreased by deficiencies in G12 and G13 (Fig.
5D). Therefore, there remains a possibility that Keap1 activity
might change in association with a signal transmitted by G12.
JNK activation increases E3 ligase activity, enhancing the
ubiquitination of target proteins, such as c-Jun and c-FLIP (5,
8). JNK-mediated phosphorylation then enhances c-Jun deg-
radation by allowing its recognition by E3 ligase protein com-
plex (8). Here, we show that G12 deficiency reduces JNK-
dependent Nrf2 ubiquitination, indicating that G12 deficiency
disrupts the ubiquitin-mediated proteasomal degradation of
Nrf2. Our findings that JNK inhibition resulted in the same
inhibitory effect on Nrf2 ubiquitination as G12 deficiency and
that JNK transfection into G12
/ cells restored ubiquitina-
tion support the hypothesis that G12 regulates the JNK-de-
pendent ubiquitination process. We recently reported that
G12 deficiency does not allow JNK to be activated in response
to sphingosine 1-phosphate (26), consequently decreasing
IB ubiquitination. Moreover, the finding that G13 defi-
FIG. 8. Schematic diagrams illustrating the proposed signaling mechanisms by which G12 and G13 regulate Nrf2 for target gene
transactivation.
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ciency also inhibited Nrf2 ubiquitination supports the concept
that both G12 and G13 are necessary for this JNK-dependent
process.
Nrf2 activation by t-BHQ may be associated with JNK acti-
vation (24). In RK/ cells, the chemical inhibition of JNK
abolished t-BHQ’s activation of Nrf2 (see Fig. S2B in the
supplemental material). However, our findings showing de-
creases by JNK overexpression in the increased nuclear Nrf2
content in G12
/ or G13
/ cells suggest that JNK may not
mediate Nrf2 phosphorylation but may regulate the ubiquiti-
nation process. Thus, it is unlikely that JNK is directly involved
in Nrf2 phosphorylation caused by G12 deficiency. It has been
shown that Nrf2 undergoes 26S-mediated proteosomal degra-
dation but is stabilized by t-BHQ treatment (37). The present
study confirms the inhibitory effect of t-BHQ on Nrf2 ubiquiti-
nation. On the basis of the data taken together, it can be
speculated that t-BHQ activates G13 with relief from the
inhibition by G12, thereby leading to Nrf2 activation and
target gene induction.
The present study shows that G12 deficiency promotes PKC
 activation and the serine phosphorylation of Nrf2. In addi-
tion, it was observed that the level of nuclear Nrf2 increases
when its ubiquitination decreases due to the absence of G12
and vice versa, which suggests that the ubiquitination of Nrf2 is
antagonistically coupled with its activation. Furthermore, our
data, which show that G13 knockdown or knockout eliminates
Nrf2 activation enhanced by G12 deficiency, support the con-
clusion that Nrf2 activation during the absence of G12 is
mediated by G13, thus verifying the antagonistic balance be-
tween G12 and G13. Therefore, it is plausible that the down-
stream signal required for the phosphorylation and nuclear
accumulation of Nrf2 might be relieved by G12 inhibition.
Our data indicate that the G13 pathway regulates Nrf2
phosphorylation via PKC  activation. The observation that
G13 deficiency abrogated the increase in Nrf2 activation due
to the absence of G12 demonstrates the crucial role of G13
in Nrf2 activation. The mechanism underlying the G12-medi-
ated repression of Nrf2 activity induced by G13 is not yet
understood. Here, we show that Nrf2 serine phosphoryla-
tion was further increased by G13QL in G12
/ and in
G12/13
/ cells, verifying that G13 activation enhances Nrf2
phosphorylation even in the absence of G12. Therefore, we
conclude that G13 controls Nrf2 activation. Gq is involved in
the phosphorylation of target proteins via PKC, which suggests
that, functionally, G12 and Gq overlap to some extent (2,
48). Moreover, because of cross talk between G12 and Gq,
there remains a possibility that the inhibition of G12 causes
the stimulation of PKC in association with Gq.
External stimuli mediated by GPCRs and cell adhesion ac-
tivate Rho (45). Rho is located in the cytoplasm as a complex
with GDI in the resting state and dissociates from GDI prior to
membrane translocation. Moreover, despite the functional
overlap between G12 and G13, only G13 stimulated the
GDP-GTP exchange of RhoA through p115RhoGEF (12).
The present study shows that G13 regulates Nrf2 via a Rho-
mediated signaling pathway.
One important result which substantiates our hypothesis
that G13 regulates Nrf2 via Rho is that DN-Rho transfection
into G12/13
/ cells completely inhibited the ability of
G13QL to activate Nrf2 or to promote ARE-mediated gene
induction. Moreover, G12 has been shown to block G13
activation of p115RhoGEF (12), which in conjunction with our
results supports the notion that Rho serves as a point of con-
vergence in Nrf2 signaling downstream of G12 and G13.
Based on the present work, we conclude that both G12 and
G13 regulate JNK-dependent Nrf2 ubiquitination but that
only G13 promotes Nrf2 activity (Fig. 8). Our proposed model
is that Nrf2 phosphorylation results from Rho-dependent ac-
tivation of PKC , which is mediated by activating G13 and
inversely by activating G12.
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